Trials / Approved For Marketing
Approved For MarketingNCT02136511
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
An Expanded Access Protocol for Idelalisib in Combination With Rituximab for Relapsed, Previously Treated Subjects With Chronic Lymphocytic Leukemia
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idelalisib | Idelalisib 150 mg tablet administered orally twice daily |
| DRUG | Rituximab | Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20. |
Timeline
- First posted
- 2014-05-13
- Last updated
- 2014-10-28
Locations
8 sites across 4 countries: United States, Ireland, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT02136511. Inclusion in this directory is not an endorsement.